"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 43 | 13 | 56 |
| 1995 | 32 | 17 | 49 |
| 1996 | 57 | 19 | 76 |
| 1997 | 60 | 22 | 82 |
| 1998 | 67 | 24 | 91 |
| 1999 | 77 | 27 | 104 |
| 2000 | 90 | 42 | 132 |
| 2001 | 94 | 43 | 137 |
| 2002 | 128 | 60 | 188 |
| 2003 | 142 | 60 | 202 |
| 2004 | 152 | 71 | 223 |
| 2005 | 152 | 62 | 214 |
| 2006 | 169 | 96 | 265 |
| 2007 | 195 | 111 | 306 |
| 2008 | 199 | 104 | 303 |
| 2009 | 199 | 120 | 319 |
| 2010 | 243 | 126 | 369 |
| 2011 | 255 | 142 | 397 |
| 2012 | 249 | 110 | 359 |
| 2013 | 238 | 119 | 357 |
| 2014 | 254 | 99 | 353 |
| 2015 | 295 | 118 | 413 |
| 2016 | 250 | 123 | 373 |
| 2017 | 229 | 99 | 328 |
| 2018 | 197 | 82 | 279 |
| 2019 | 158 | 76 | 234 |
| 2020 | 158 | 58 | 216 |
| 2021 | 175 | 55 | 230 |
| 2022 | 118 | 10 | 128 |
| 2023 | 130 | 6 | 136 |
| 2024 | 44 | 65 | 109 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Pharmacologic Blockade of a Pioneer Transcription Factor. Cancer Res. 2024 Dec 16; 84(24):4124-4125.
-
Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V. JCO Precis Oncol. 2024 Dec; 8:e2400514.
-
BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia. Cells. 2024 Nov 20; 13(22).
-
BCL-2 inhibition in acute myeloid leukemia: resistance and combinations. Expert Rev Hematol. 2024 Dec; 17(12):935-946.
-
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature. 2024 Dec; 636(8041):241-250.
-
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II?trial. Future Oncol. 2024; 20(38):3065-3075.
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
-
Small-Molecule CCR4 Antagonists in Cutaneous T-cell Lymphoma. Cancer Res Commun. 2024 Oct 01; 4(10):2756-2765.
-
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERN. Haematologica. 2024 Oct 01; 109(10):3251-3260.
-
A brave new framework for glioma drug development. Lancet Oncol. 2024 Oct; 25(10):e512-e519.